Cadila spikes 2 per cent on USFDA approval
Zydus Cadila has received the approval from the US Food and Drug Administration (USFDA) to market Rivastigmine Transdermal System.
Rivastigmine Transdermal System 4.6 mg/24 hrs, 9.5 mg/24 hrs and 13.3 mg/24 hrs, is indicated for the treatment of dementia that is associated with Alzheimer’s and Parkinson’s diseases. It will be manufactured at Zydus Technologies' facility which is dedicated to the production of transdermal located at SEZ, Ahmedabad, Gujarat.
The pharma major has also received the final approval for Rosuvastatin Tablets USP in the strengths of 5 mg, 10 mg, 20 mg, and 40 mg. Rosuvastatin Tablets will be manufactured at the company’s formulations facility at SEZ, Ahmedabad.
Rosuvastatin helps in lowering bad cholesterol and triglycerides and raising good cholesterol which results in decreasing the risk of heart disease, thereby preventing strokes and heart attacks.
On Tuesday, the stock of Cadila Healthcare closed at Rs. 331.20, up by 2.4 per cent. It's intraday high was Rs. 332.50 and intraday low was Rs. 321 per share on BSE. Meanwhile, the BSE Sensex closed at 36,442.54 level, up by 378 points or 1.05 per cent